Dizhe Pharmaceutical (688192.SH): Schwarzhe received accelerated approval from the US FDA for listing

Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that the new drug marketing application (NDA) for Schwarzhe® (English product name: ZEGFROVY®, generic name: suvortinib tablets) independently developed by the company has been officially approved by the US Food and Drug Administration (FDA) for use in the past when the disease progresses during or after treatment with platinum-containing chemotherapy, and it has been confirmed by an FDA-approved kit test that there is partial metastasis or advanced metastasis of epidermal growth factor receptor (EGFR) exon insertion mutation 20 (exon20ins) Sex is not small Adult patients with cellular lung cancer (NSCLC).